Indeed, ABZ treatment significantly increased the CD8+ T cell proportion (online supplemental figure 2F, G) and GZMB+ CD8+ T cell proportion (figure 1L, M) in both melanoma B16F10 and LLC tumor-bearing immune-competent mouse models. Here, CD8A is linked to melanoma.